Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment
Halberd Corporation (OTC PINK: HALB) has filed an International Patent Cooperation Treaty (PCT) application for its invention titled Covid-19 Inflammatory Cytokine Storm Treatment. This application expands its patent protection across over 150 countries. The treatment aims to tackle Covid-19 and other diseases via a patented extracorporeal process, with current experiments being conducted in collaboration with GreenBioAZ and Youngstown State University. Halberd also holds exclusive rights to multiple related technologies and has filed various provisional patent applications concerning Covid-19 treatments.
- International PCT application filed for Covid-19 Inflammatory Cytokine Storm Treatment, enhancing global patent protection.
- Collaboration with GreenBioAZ and Youngstown State University for experimental treatments.
- Exclusive worldwide rights to several patent- and PCT-pending Covid-19 treatments, indicating a strong intellectual property portfolio.
- Forward-looking statements indicate significant risks and uncertainties regarding future performance.
- Potential regulatory scrutiny from the SEC concerning claims related to COVID-19 initiatives.
JACKSON CENTER, PA / ACCESSWIRE / April 12, 2021 / Halberd Corporation (OTC PINK:HALB) filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, "Covid-19 Inflammatory Cytokine Storm Treatment." The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "We sought patent protection beyond the U.S. through the PCT process, thus we are able to protect our technology in many countries across the globe. Halberd's patented extracorporeal treatment process opens the door to treatment of Covid-19 and other diseases through radiofrequency elimination (experimentation already underway simultaneously with GreenBioAZ and Youngstown State University). Laser ablation methodologies are also being explored currently with a European technology source, but are considered a bigger technology hurdle due to the requirement for high-speed computer targeting required for the laser.
The Halberd U.S. provisional patent application "Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients" was initially filed with the U.S. Patent and Trademark Office on April 8, 2020. Halberd holds exclusive worldwide license to this technology.
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending COVID-19 extracorporeal treatments:
Title | Patent/ Application No. | Filing Date | Status/Document |
*Method for Treating and Curing Covid-19 Infection | US 62/989981 | 03/16/2020 | Provisional provisional_COVID-19_kk,4823-1130-2071.docx |
PCT/US21/22541 | 03/16/2021 | International PCT | |
*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients | US 63/007207 | 04/08/2020 | Provisional Cytokine-provisional-kk,4826-5866-1817.docx |
Covid-19 Inflammatory Cytokine Storm Treatment | PCT/US21/26386 | 04/08/2021 | International PCT |
*Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus | US 63/013104 | 04/21/2020 | Provisional Laser Method for Treating and Curing Covid,4834-1487-7370.docx |
*Method For The Rapid Identification Of Covid-19 Infection | US 63/049441 | 07/08/2020 | Provisional Rapid Covid detection.pdf |
*Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans | US 63/080735 | 09/20/2020 | Provisional Nasal Spray prov appl.pdf |
*Nasal Spray To Prevent The Transmission Of The Covid-19 Virus | US 63/108301 | 10/31/202 | Provisional Nasal Spray to prevent spread prov appl.pdf |
*Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus | US 63/111043 | 11/08/2020 | Provisional Covid RF eradication.pdf |
*Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus) | US 63/135695 | 01/10/2021 | Provisional Spec_2101.pdf |
Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/639871/Halberd-Corporation-Files-International-Patent-Cooperation-Treaty-PCT-Application-on-Covid-19-Inflammatory-Cytokine-Storm-Treatment
FAQ
What is the purpose of Halberd Corporation's PCT application?
What collaborative efforts is Halberd involved in regarding Covid-19 treatments?
What patents does Halberd Corporation hold related to Covid-19?
What risks does Halberd Corporation face according to their press release?
When was Halberd Corporation's provisional patent application filed?
